Taiwan industry looking for progress on pricing under new minister
This article was originally published in Scrip
Pharmaceutical industry groups in Taiwan are planning to meet the new minister of health early next month to discuss their objections to the general drug price cut scheduled for September 1st.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.